Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia
COMMIT: Triplet regimen extends PFS in select CRC patients
04 Feb 2026
bởiAudrey Abella
In the phase III COMMIT* trial, a combination of mFOLFOX6 (FFX), atezolizumab, and bevacizumab significantly improves progression-free survival (PFS) in patients with deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer (dMMR/MSI-H mCRC).
COMMIT: Triplet regimen extends PFS in select CRC patients
04 Feb 2026
NATALEE updates: Ribociclib benefit in HR+, ERBB– EBC sustained at 4 years
03 Feb 2026
bởiAudrey Abella
In an updated analysis of the NATALEE* trial, the efficacy benefit of adjuvant ribociclib remains consistent even after the planned 3-year treatment duration for patients with HR+, ERBB2– early breast cancer (EBC).